Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tirofiban for Patients Treated With Alteplase
NCT03357133 · Capital Medical University · PHASE2/PHASE3 · terminated · last registry update 2020-09-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The number and speed of enrollment were significantly less than expected.” | – | Registry record, Capital Medical University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGB3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-04-20Results posted on the registry: Medicure, Short Tirofiban + Eptifibatide (NCT01522417)
- 2021-04-01Phase 3 first posted: CeleCor Therapeutics, zalunfiban + Placebo (NCT04825743)
- 2020-07-29Phase 3 first posted: Capital Medical University, Tirofiban Hydrochloride + Oral antiplatelet (NCT04491695)
- 2020-03-18Also stopped (withdrawn): SFJ Pharmaceuticals X, LTD., abituzumab + Placebo + Cetuximab + FOLFIRI (NCT03688230)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision